23 Nov 2023 , 02:52 PM
Lupin Limited launches world’s first fixed-dose triple combination drug, Vilfuro-G, for COPD treatment in India. Approval granted by the Drug Controller General of India for the dry powder inhaler (DPI) product.
Vilfuro-G is the only FDC combining vilanterol, fluticasone furoate, and glycopyrronium bromide for moderate to severe COPD. The product addresses the long-term management of COPD, affecting over 37 million individuals in India.
Lupin’s Q2 consolidated net profit rose 3.77-fold YoY to Rs 489.6 crore, with revenue at Rs 5038.56 crore, up 24.9% from the previous year.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.